News & Perspective

Nov 17, 2017

Nov 17, 2017

ASP Scan (Weekly) for Nov 17, 2017

Primary care stewardship
No-touch superbug disinfection
Surgical antimicrobial prescribing
Ceftriaxone-resistant gonorrhea
E coli ST131
Single-room ICU design
ECDC CRE guidance
European research funding
Optimal MDR-TB treatment
Real-time resistance tracker
Salmonella in calves
Drug-resistant malaria controversy
US AMR progress
Antimicrobial use in Northern Ireland
Resistance in space

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Aug 18, 2009

Aug 18, 2009

FDA clears CSL's vaccine-finishing facility in US

(CIDRAP News) – The US Food and Drug Administration (FDA) today approved a vaccine filling and packaging facility in Illinois owned by CSL Biotherapies, one of the five companies under contract to make novel H1N1 vaccines for the United States, the company announced.

Sort Results

 

Narrow results

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»